Huge news for the Platelet Rich Plasma (PRP) world was just released. The Centers for Medicare and Medicaid Services (CMS) proposes that platelet-rich plasma (PRP) – an autologous blood-derived product, will be covered only for the treatment of chronic non-healing diabetic, venous and/or pressure wounds.
We will be covering this story and updating THIS POST as more news comes out.
Update: CMXI stock has risen huge amounts since this news. A few months back it was .30 cents and now sits at $1.82 per share – it’s still on the rise.
Links related to PRP Approval by the CMS:
- CMS Decision Summary
- Yahoo Finance!
- CMXI Cytomedix Forum on Yahoo
- PRP Approved by CMS for Chronic Wounds
- CMS Coverage Big Positive For Cytomedix – Seeking Alpha
What PRP Experts are Saying about this CMS Coverage Decision
- Dr. Allan Mishra tweeted – “Preliminary coverage by CMS of platelet rich plasma for wounds will encourage research & development of new PRP applications”